Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
posted on
Mar 30, 2020 09:30AM
They could have worded that part better to indicate that the 10.3% and 12.4% were referring to the 3-point MACE event rates in the apabetalone and placebo groups, respectively.
BDAZ